Literature DB >> 17206937

Pathway of biogenesis of apolipoprotein E-containing HDL in vivo with the participation of ABCA1 and LCAT.

Kyriakos E Kypreos1, Vassilis I Zannis.   

Abstract

We have investigated the ability of apoE (apolipoprotein E) to participate in the biogenesis of HDL (high-density lipoprotein) particles in vivo using adenovirus-mediated gene transfer in apoA-I-/- (apolipoprotein A-I) or ABCA1-/- (ATP-binding cassette A1) mice. Infection of apoA-I-/- mice with 2x10(9) pfu (plaque-forming units) of an apoE4-expressing adenovirus increased both HDL and the triacylglycerol-rich VLDL (very-low-density lipoprotein)/IDL (intermediate-density lipoprotein)/LDL (low-density lipoprotein) fraction and generated discoidal HDL particles. ABCA1-/- mice treated similarly failed to form HDL particles, suggesting that ABCA1 is essential for the generation of apoE-containing HDL. Combined infection of apoA-I-/- mice with a mixture of adenoviruses expressing both apoE4 (2x10(9) pfu) and human LCAT (lecithin:cholesterol acyltransferase) (5x10(8) pfu) cleared the triacylglycerol-rich lipoproteins, increased HDL and converted the discoidal HDL into spherical HDL. Similarly, co-infection of apoE-/- mice with apoE4 and human LCAT corrected the hypercholesterolaemia and generated spherical particles, suggesting that LCAT is essential for the maturation of apoE-containing HDL. Overall, the findings indicate that apoE has a dual functionality. In addition to its documented functions in the clearance of triacylglycerol-rich lipoproteins, it participates in the biogenesis of HDL-sized apoE-containing particles. HDL particles generated by this pathway may account at least for some of the atheroprotective functions of apoE.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17206937      PMCID: PMC1874240          DOI: 10.1042/BJ20061048

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  41 in total

1.  Low levels of extrahepatic nonmacrophage ApoE inhibit atherosclerosis without correcting hypercholesterolemia in ApoE-deficient mice.

Authors:  F E Thorngate; L L Rudel; R L Walzem; D L Williams
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-08       Impact factor: 8.311

2.  Domains of apolipoprotein E contributing to triglyceride and cholesterol homeostasis in vivo. Carboxyl-terminal region 203-299 promotes hepatic very low density lipoprotein-triglyceride secretion.

Authors:  K E Kypreos; K W van Dijk; A van Der Zee; L M Havekes; V I Zannis
Journal:  J Biol Chem       Date:  2001-02-09       Impact factor: 5.157

3.  Hepatic expression of apolipoprotein E inhibits progression of atherosclerosis without reducing cholesterol levels in LDL receptor-deficient mice.

Authors:  K Tsukamoto; R K Tangirala; S Chun; D Usher; E Puré; D J Rader
Journal:  Mol Ther       Date:  2000-02       Impact factor: 11.454

4.  High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase.

Authors:  I S Yuhanna; Y Zhu; B E Cox; L D Hahner; S Osborne-Lawrence; P Lu; Y L Marcel; R G Anderson; M E Mendelsohn; H H Hobbs; P W Shaul
Journal:  Nat Med       Date:  2001-07       Impact factor: 53.440

5.  Apolipoprotein E is the major physiological activator of lecithin-cholesterol acyltransferase (LCAT) on apolipoprotein B lipoproteins.

Authors:  Yue Zhao; Fayanne E Thorngate; Karl H Weisgraber; David L Williams; John S Parks
Journal:  Biochemistry       Date:  2005-01-25       Impact factor: 3.162

6.  Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1.

Authors:  M Navab; S Y Hama; C J Cooke; G M Anantharamaiah; M Chaddha; L Jin; G Subbanagounder; K F Faull; S T Reddy; N E Miller; A M Fogelman
Journal:  J Lipid Res       Date:  2000-09       Impact factor: 5.922

7.  Loss of SR-BI expression leads to the early onset of occlusive atherosclerotic coronary artery disease, spontaneous myocardial infarctions, severe cardiac dysfunction, and premature death in apolipoprotein E-deficient mice.

Authors:  Anne Braun; Bernardo L Trigatti; Mark J Post; Kaori Sato; Michael Simons; Jay M Edelberg; Robert D Rosenberg; Mark Schrenzel; Monty Krieger
Journal:  Circ Res       Date:  2002-02-22       Impact factor: 17.367

8.  Rapid regression of atherosclerosis induced by liver-directed gene transfer of ApoE in ApoE-deficient mice.

Authors:  K Tsukamoto; R Tangirala; S H Chun; E Puré; D J Rader
Journal:  Arterioscler Thromb Vasc Biol       Date:  1999-09       Impact factor: 8.311

9.  High density lipoprotein deficiency and foam cell accumulation in mice with targeted disruption of ATP-binding cassette transporter-1.

Authors:  J McNeish; R J Aiello; D Guyot; T Turi; C Gabel; C Aldinger; K L Hoppe; M L Roach; L J Royer; J de Wet; C Broccardo; G Chimini; O L Francone
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-11       Impact factor: 11.205

10.  Generation of a recombinant apolipoprotein E variant with improved biological functions: hydrophobic residues (LEU-261, TRP-264, PHE-265, LEU-268, VAL-269) of apoE can account for the apoE-induced hypertriglyceridemia.

Authors:  Kyriakos E Kypreos; Ko W van Dijk; Louis M Havekes; Vassilis I Zannis
Journal:  J Biol Chem       Date:  2004-12-02       Impact factor: 5.157

View more
  30 in total

1.  A2b adenosine receptor regulates hyperlipidemia and atherosclerosis.

Authors:  Milka Koupenova; Hillary Johnston-Cox; Alexander Vezeridis; Haralambos Gavras; Dan Yang; Vassilis Zannis; Katya Ravid
Journal:  Circulation       Date:  2011-12-05       Impact factor: 29.690

2.  Role of the hydrophobic and charged residues in the 218-226 region of apoA-I in the biogenesis of HDL.

Authors:  Panagiotis Fotakis; Andreas K Kateifides; Christina Gkolfinopoulou; Dimitra Georgiadou; Melissa Beck; Katharina Gründler; Angeliki Chroni; Efstratios Stratikos; Dimitris Kardassis; Vassilis I Zannis
Journal:  J Lipid Res       Date:  2013-08-29       Impact factor: 5.922

3.  Domains of apoE4 required for the biogenesis of apoE-containing HDL.

Authors:  Alexander M Vezeridis; Angeliki Chroni; Vassilis I Zannis
Journal:  Ann Med       Date:  2011-06       Impact factor: 4.709

Review 4.  High-density lipoprotein (HDL) metabolism and bone mass.

Authors:  Nicholaos I Papachristou; Harry C Blair; Kyriakos E Kypreos; Dionysios J Papachristou
Journal:  J Endocrinol       Date:  2017-03-17       Impact factor: 4.286

5.  An apolipoprotein E4 fragment affects matrix metalloproteinase 9, tissue inhibitor of metalloproteinase 1 and cytokine levels in brain cell lines.

Authors:  I Dafnis; A K Tzinia; E C Tsilibary; V I Zannis; A Chroni
Journal:  Neuroscience       Date:  2012-03-14       Impact factor: 3.590

6.  apoE3[K146N/R147W] acts as a dominant negative apoE form that prevents remnant clearance and inhibits the biogenesis of HDL.

Authors:  Panagiotis Fotakis; Alexander Vezeridis; Ioannis Dafnis; Angeliki Chroni; Dimitris Kardassis; Vassilis I Zannis
Journal:  J Lipid Res       Date:  2014-04-28       Impact factor: 5.922

7.  Allele-dependent thermodynamic and structural perturbations in ApoE variants associated with the correction of dyslipidemia and formation of spherical ApoE-containing HDL particles.

Authors:  Dimitra Georgiadou; Angeliki Chroni; Konstantinos Drosatos; Kyriakos E Kypreos; Vassilis I Zannis; Efstratios Stratikos
Journal:  Atherosclerosis       Date:  2012-11-23       Impact factor: 5.162

8.  Genetic variation and atherosclerosis.

Authors:  Erik Biros; Mirko Karan; Jonathan Golledge
Journal:  Curr Genomics       Date:  2008-03       Impact factor: 2.236

9.  An apoA-I mimetic peptide increases LCAT activity in mice through increasing HDL concentration.

Authors:  Xun Chen; Charlotte Burton; Xuelei Song; Lesley McNamara; Annunziata Langella; Simona Cianetti; Ching H Chang; Jun Wang
Journal:  Int J Biol Sci       Date:  2009-07-28       Impact factor: 6.580

10.  Role of Esrrg in the fibrate-mediated regulation of lipid metabolism genes in human ApoA-I transgenic mice.

Authors:  D Sanoudou; A Duka; K Drosatos; K C Hayes; V I Zannis
Journal:  Pharmacogenomics J       Date:  2009-12-01       Impact factor: 3.550

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.